[Skip to Navigation]
May 1965

Use of an Oral Corticosteroid In the Treatment Of Multiple Sclerosis: A Double-Blind Study

Author Affiliations

From the Department of Neurology, University of Michigan.

Arch Neurol. 1965;12(5):536-545. doi:10.1001/archneur.1965.00460290092010

THE PURPOSE of this report is to present the results of a double-blind drug trial in which an oral corticosteroid, methylprednisolone (Medrol), was compared to oral cyanocobalamin (vitamin B12) in patients with multiple sclerosis.

This pair of drugs was chosen for comparison for several reasons. If multiple sclerosis is a peculiar auto-immune disease related to the myelin of the brain, then it might be reasonable to expect that corticosteroids may favorably alter the course of the disease.1 A number of reports in the recent literature have dealt with clinical trials of corticosteroids and corticotropin (ACTH) in the treatment of patients with multiple sclerosis. Studies by Alexander et al on corticotropin,2,3 which did not include modern statistical designs such as randomization of administration of placebo and corticotropin and a double-blind technique, have indicated a favorable response. Miller et al,4 utilizing a modern statistical design, also concluded that corticotropin

Add or change institution